Breaking Finance News

A statement released earlier today by National Bank Financial about Theratechnologies Inc. (TSE:TH) bumps the target price to $3.25

Having a price of $2.87, Theratechnologies Inc. (TSE:TH) traded 3.57% higher on the day. With the last close up 19.81% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the same period. Theratechnologies Inc. has recorded a 50-day average of $2.61 and a two hundred day average of $2.42. Volume of trade was down over the average, with 97,472 shares of TH changing hands under the typical 124,332

National Bank Financial upped the price target of Theratechnologies Inc. (TSE:TH) to $3.25 reporting a potential upside of 0.13%.

On 07/07/2016, Canaccord Genuity released a statement on Theratechnologies Inc. (TSE:TH) dropped the target price from $4.25 to $3.75 that suggested an upside of 0.54%.

Performance Chart

Theratechnologies Inc. (TSE:TH)

With a total market value of $0, Theratechnologies Inc. has price-earnings ratio of 263.64 with a one year low of $1.26 and a one year high of $3.74 .

A total of 4 analysts have released a research note on Theratechnologies Inc.. Two analysts rating the company a strong buy, one analyst rating the company a buy, one analyst rating the company a hold, zero analysts rating the company a underperform, and finally zero analysts rating the company a sell with a 12-month price target of $3.22.

More About Theratechnologies Inc. (TSE:TH)

Theratechnologies Inc. is a Canada-based specialty pharmaceutical company. The Company addresses medical needs in metabolic disorders to promote healthy ageing among human immunodeficiency virus (HIV) patients. The Company's product, EGRIFTA (tesamorelin for injection), is used for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. The Company's EGRIFTA is indicated for the treatment of excess visceral adipose tissue (VAT).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *